Farallon Capital Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Farallon Capital Management’s Portfolio DCPH Stock Details DCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-300,000	Closed	-$13.5M	–	318
2021 Q1	$13.5M	Hold	300,000	–	–	0.07%	121
2020 Q4	$17.1M	Sell	300,000 -30,000	-9%	-$1.78M	0.1%	93
2020 Q3	$16.9M	Sell	330,000 -385,000	-54%	-$18.9M	0.12%	89
2020 Q2	$42.7M	Sell	715,000 -285,000	-29%	-$15.2M	0.34%	61
2020 Q1	$41.2M	Buy	1,000,000 +50,000	+5%	+$2.78M	0.35%	49
2019 Q4	$59.1M	Buy	950,000 +200,000	+27%	+$9.51M	0.4%	50
2019 Q3	$25.5M	Buy	+750,000	New	+$22.2M	0.19%	63
2017 Q4	–	Sell	-100,000	Closed	-$1.9M	–	91
2017 Q3	$1.9M	Buy	+100,000	New	+$1.83M	0.02%	84

Other funds holding DCPH

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Farallon Capital Management's DCPH Position: Q2 2021 in Review

Farallon Capital Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2021, closing a stake of 300,000 shares — an estimated $13.5M sold.

Farallon Capital Management first reported a position in DCPH in Q3 2017 and held it in 8 quarters. The position peaked at $59.1M in Q4 2019. 147 funds tracked by Wall St. Rank hold DCPH as of Q2 2021.

Farallon Capital Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Farallon Capital Management sold 300,000 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2021, an estimated $13.5M.
Farallon Capital Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2017 and held it in 8 quarters.
Farallon Capital Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $59.1M in Q4 2019.
147 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2021.

Based on Farallon Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.